Results 161 to 170 of about 20,678 (258)

Global research trends on DPP-4 inhibitors and cardiovascular outcomes: a comprehensive bibliometric analysis. [PDF]

Ann Med Surg (Lond)
Amini-Salehi E, Hasanpour M, Alotaibi A, Rashidian P, Hashemi SM, Nasrollahizadeh A, Letafatkar N, Saberian P, Amani-Beni R, Shanbehzadeh N.   +9 more
europepmc   +1 more source

Frailty and low body mass index as key determinants of sodium‐glucose cotransporter 2 inhibitor‐specific adverse event‐related discontinuation in adults aged ≥75 years: A multicenter real‐world retrospective cohort study

Journal of Diabetes Investigation, EarlyView.
Among Japanese adults aged ≥75 years newly initiating SGLT2 inhibitors, SGLT2 inhibitor–specific adverse event‐related discontinuation occurred in 9.1% within 180 days. Frailty and low BMI, rather than chronological age, were the key predictors, highlighting the importance of assessing physiological reserve before treatment initiation.
Taisuke Uchida, Hiroaki Ueno, Ayaka Konagata, Hiroki Nabekura, Yuki Kikuchi, Takumi Beppu, Akari Sekishima, Hirotaka Sekishima, Takayuki Nakamura, Fumiko Kogo, Yudai Uehira, Yuri Tanaka, Hideki Yamaguchi, Kazuya Shimoda   +13 more
wiley   +1 more source

Retraction: Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: A systematic review and meta-analysis. [PDF]

PLoS One
PLOS One Editors.
europepmc   +1 more source

Association of DPP-4 inhibitors with respiratory and cardiovascular complications in patients with COPD: a nationwide cohort study. [PDF]

ERJ Open Res
Yen FS, Wei JC, Ko FS, Huang Y, Yip HT, Tsai FJ, Hwu CM, Hsu CC.   +7 more
europepmc   +1 more source

Do Intoxicated Offenders Deserve Harsher Sentences? Questioning Veritas in Vino

Journal of Social Philosophy, EarlyView.
ABSTRACT Criminal courts increasingly treat intoxication as an aggravating rather than a mitigating factor in sentencing. This shift, seen in Australian law and other jurisdictions, raises the prospect of unjust outcomes. We examine this trend through the lens of desert‐based justifications for punishment, setting aside questions of deterrence and ...
Mary Jean Walker, Daniel B. Cohen
wiley   +1 more source

Beyond glycemic control: the cardiac and hepatic benefits of SGLT2 and DPP-4 inhibitors in mitigating chronic cadmium-induced inflammation, oxidative/nitrative stress, apoptosis and fibrosis. [PDF]

Front Physiol
Hassan FE, Hassanien MM, Selmy A, Mahmoud LM, Darwish A, Aldreny BA.   +5 more
europepmc   +1 more source

Asymmetric Synthesis of a DPP-4 Inhibitor [PDF]

Synfacts, 2014
openaire   +1 more source

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms

Obesity Reviews, EarlyView.
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani, Tzu‐Wen L. Cross, Erica de Jong, Emily S. Glover, Ivan D. Mendoza, Mojisola Adisa, Keigo Tomoo, Xinyi Zhou, Richard D. Mattes   +8 more
wiley   +1 more source

Cardiovascular Sequel in Type-2 Diabetes Mellitus Patients on Various Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systemic Review and Meta-Analysis. [PDF]

Cureus
Prakash V, Goel N.
europepmc   +1 more source

DPP-4 Inhibitors as Antidiabetic Agents

Journal of Analytical & Bioanalytical Techniques, 2010
openaire   +1 more source